- Home
- MGNI vs IMCR Comparison
MGNI vs IMCR Comparison
Compare MGNI & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNI
- IMCR
- Stock Information
- Founded
- MGNI 2007
- IMCR 2008
- Country
- MGNI United States
- IMCR United Kingdom
- Employees
- MGNI N/A
- IMCR N/A
- Industry
- MGNI Computer Software: Programming Data Processing
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MGNI Technology
- IMCR Health Care
- Exchange
- MGNI Nasdaq
- IMCR Nasdaq
- Market Cap
- MGNI 1.8B
- IMCR 1.4B
- IPO Year
- MGNI N/A
- IMCR 2021
- Fundamental
- Price
- MGNI $11.40
- IMCR $28.63
- Analyst Decision
- MGNI Strong Buy
- IMCR Buy
- Analyst Count
- MGNI 14
- IMCR 12
- Target Price
- MGNI $19.25
- IMCR $63.00
- AVG Volume (30 Days)
- MGNI 2.5M
- IMCR 394.6K
- Earning Date
- MGNI 05-07-2025
- IMCR 05-07-2025
- Dividend Yield
- MGNI N/A
- IMCR N/A
- EPS Growth
- MGNI N/A
- IMCR N/A
- EPS
- MGNI 0.16
- IMCR N/A
- Revenue
- MGNI $668,170,000.00
- IMCR $310,202,000.00
- Revenue This Year
- MGNI $2.23
- IMCR $18.97
- Revenue Next Year
- MGNI $10.93
- IMCR $8.43
- P/E Ratio
- MGNI $69.97
- IMCR N/A
- Revenue Growth
- MGNI 7.82
- IMCR 24.36
- 52 Week Low
- MGNI $8.38
- IMCR $27.19
- 52 Week High
- MGNI $21.29
- IMCR $64.47
- Technical
- Relative Strength Index (RSI)
- MGNI 29.36
- IMCR 44.70
- Support Level
- MGNI $10.86
- IMCR $28.00
- Resistance Level
- MGNI $13.71
- IMCR $30.50
- Average True Range (ATR)
- MGNI 0.69
- IMCR 1.44
- MACD
- MGNI -0.03
- IMCR 0.01
- Stochastic Oscillator
- MGNI 18.95
- IMCR 17.76
About MGNI Magnite Inc.
Magnite Inc is one of the supply-side platform providers, or SSP, in online advertising. The firm generate its revenue from the programmatic sale of CTV ad inventory, from mobile online sites and apps, and the remaining from websites accessed via computer.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.